Contact Info
Email:
jennifer dot hinkel at kellogg dot ox.ac.uk
At the University of Oxford...
I'm working on a DPhil in Evidence Based Health Care, supervised by Dr. Carl Heneghan and Dr. Clare Bankhead at Oxford's Centre for Evidence Based Medicine (CEBM). You can find my ResearchGate page here and a preprint coming from this research here. My research topic is on endpoint fidelity and definition in cancer clinical trials, with a focus on non-small cell lung cancer (NSCLC)
And elsewhere...
I lead the strategic consultancy and creative agency Sigla Sciences, specializing in advisement to the biopharma and life sciences sector. We also advise biopharma and healthcare firms on how to integrate new technologies such as AI into their businesses, and we train companies to use strategic foresight and long-term future forecasting to help become "future-proof." We also sponsor the BioUpdates.AI newsletter
Since 2023, I have been an advisor to NASA as part of the Convergent Aeronautic Solutions group — NASA's strategic foresight and futurism team. Recently, we have been working to forecast and simulate the future of aviation, airports, and air travel.
And also...
I'm a Director at The Data Economics Company (DECO), a venture-backed tech startup pioneering the science of data economics through the Lydion operating system, a method for packaging and assetizing data to unlock new economic opportunities for firms and individuals. I'm a co-inventor of DECO's technology, and write about how Data Economics will shape the future as part of the Center for Data Economics Innovation and Research (CDEIR), a virtual think tank backed by DECO.
I am also a Director at Popularium, Inc., a venture-backed video game company behind the title Chaos Agents that leverages Lydion technology.
I'm one of the co-Editors-in-Chief at the open-access journal Blockchain in Healthcare Today: Platform Approaches in Healthcare, working to bridge technologist, clinician, and health policy perspectives on how new information technologies can be leveraged to advance human health and improve health systems.
Thanks for stopping by, and please reach out to me on LinkedIn if you want to get in touch about research or business collaborations.
For my bio, CV/publication highlights, and more, keep scrolling down.
Recent Articles
In STAT News: Getting Health Companies to Play Fair with Patient Data
In MedCity News: Across Healthcare, Companies Are Profiting From Data. When Will Providers and Patients Get Their Share of the Winnings?
Selected Academic Publications, Abstracts, and Presented Papers
Hinkel, Jennifer, Carl Heneghan, and Clare Bankhead. 2024. Selective Outcome Reporting in Cancer Studies: A Scoping Review. medRxiv. https://doi.org/10.1101/2024.07.02.24309826.
Hinkel JM, Benton J, Kavade R, Kulig K, Fonseca R, Knopf KB. Oncology biomarker recommendations for gastrointestinal cancers as part of ONCOMARKR: The oncology biomarker review project. Annals of Oncology. ESMO GI Conference 2024. Vol 35, S1, S202, June 2024.
Hinkel JM. Indexing Regulatory Documents and Clinical Evidence Publications for Non-Small Cell Lung Cancer (NSCLC) Therapeutics: Establishing a Dataset to Enable the Study of Endpoint Fidelity. Poster Presentation, International Society for Pharmacoeconomic and Outcomes Research. Value in Health 25(Supp 2), July 2022.
Hinkel JM. Towards a more systematic evaluation of cancer endpoints: A method for synthesis and analysis of NSCLC regulatory filings and clinical evidence. Published Abstract, American Society of Clinical Oncology Annual Meeting, June 2022.
Yates N, Hinkel JM. The Economics of Moonshots: Value in rare disease drug development. Clinical Translational Science. 2022 April; 15(4): 809–812.
Gorman T, Brar SS, Ray A, Hinkel JM. Advancing Outcomes-Based Pharmaceutical Reimbursement Models Using Structured Risk and Investment Funding. Published Abstract, International Society for Pharmacoeconomic and Outcomes Research, Value in Health 23(Supp 2), December 2020.
Hinkel JM, Gorman T, Brar SS, Ray A. Developing a real-world outcomes forecast model using matched oncology clinical trials and real world evidence to inform policy-making and reimbursement approaches. Proffered Paper, European Society for Medical Oncology, September 2020.
Hinkel JM, Brar SS, Ray A. A Conceptual Framework for Valuation and Utility of Non-Clinical Outcomes. Virtual Poster Presentation, International Society for Pharmacoeconomic and Outcomes Research, May 2020.
Conway M, Malandrucco D, Hinkel JM. Modeling Geographic Barriers to Ovarian Cancer Clinical Trials in Pennsylvania. Pennsylvania Geographer 2019; 57 (2): 16-31.
Hinkel JM, Brar SS, Lalmalani RJ, et al. Proposing and evaluating a design for GDPR-compliant, scalable technology for automatic adjudication of risk-sharing agreements. Value in Health. 2019;22:S769.
Hinkel JM, Ray A, Brar S, et al. Modeling an oncology outcomes-based contract using a blockchain database approach: Cost and technology considerations. J Clin Oncol 2019;37:e18360–e18360.
Fonseca R et al. Cost vs. Value and the Price of Innovation in Cancer Care. Goldwater Inst. 2018. Epub.
Hinkel J, Dean B, McGivney WT. Evaluating a Conceptual Platform for Facilitating and Scaling Pharmaceutical Risk Sharing Agreements. Poster Presentation, ISPOR 21st Annual International Meeting. May 2018.
Hinkel JM, Sexton DB. Exploring cancer survivor perspectives on the value of life and time post-diagnosis. Poster Presentation, ISPOR 22nd Annual International Meeting. May 2017. Abstract PCN164.
Hinkel JM, Sexton DB, Egan-Kunicki J. Value of life and time: A survivorship perspective. J. Clin. Oncology 2017 35:15_supple, e18298.
Hinkel JM, Sexton D, McGivney WT. Forecasting Financial Impact of Alternative Payment Models to Cancer Drug Manufacturers. J. Clin. Oncology 2017 ASCO Ann Mtg Proceedings. 35 (15): 6549.
Lyle JL, Vandergrift JL, Hinkel, JM, Lepisto EM, Cortazzo KA, Sherman S, Stewart FM. Influential Factors for Post-Fellowship Career Decision-Making: An NCCN Survey. J. Natl Compr Canc Netw. 2012;10:969-974.
Hinkel JM, Li EC, Sherman SL. Insights and perspectives in the clinical and operational management of cancer-related anemia. J. Natl Compr Canc Netw. 2010 Sep;8 Suppl 7:S38-55
Schwartz RN, Eng KJ, Frieze DA, Gosselin TK, Griffith N, Seung AH, Hinkel JM, Johnson PE, Johnson SA, Li EC, Szabatura AH, Wong MK. NCCN Task Force Report: Specialty Pharmacy. J. Natl Compr Canc Netw. 2010 Jul;8 Suppl 4:S1-12.
Hinkel JM, Vandergrift JL, Perkel SJ, Waldinger MB, Levy W, Stewart FM. Practice and productivity of physician assistants and nurse practitioners in outpatient oncology clinics at national comprehensive cancer network institutions. J. Oncol Pract. 2010 Jul;6(4):182-7. Epub 2010 Jun 23
Hinkel JM, Vandergrift JL, Lepisto EM, Minogue KA, Stewart FM. Fellowship characteristics associated with fellows’ interest in pursuing clinical research: A NCCN survey. J. Clin. Oncology 2010 ASCO Ann Mtg Proceedings. 28 (15): 6157.
Li EC, Hinkel JM, Gallagher L, DeVader SR, Vandergrift JL, Lepisto EM. NCCN Chemotherapy Order Templates: Enhancing patient safety through standardization. Amer. Soc. of Clin. Oncology 2009. Published Abstract.
Hinkel JM, Vandergrift JL, Perkel SJ, Waldinger MB, Levy W, Stewart FM. The impact of mid-level providers on productivity in outpatient oncology clinics at National Comprehensive Cancer Network (NCCN) institutions. Amer. Soc. of Clin. Oncology 2009.
Hinkel JM. Addressing issues in patient safety. J. Natl Compr Canc Netw. 2007 Apr; 5(4):360-2
Patents and Patent Applications
Hinkel JM. Method and system for authenticating and monitoring home health interactions. U.S. Patent 9,703,931 filed June 6, 2012 and issued July 11, 2017, and U.S. Patent 10,607,731, filed June 6, 2017, and issued March 31, 2020.
Hinkel JM, Ray A. Systems and methods of generating, validating, approving, recording, and utilizing digital data assets in a blockchain platform using a transactional proof of work. U.S. Patent 11,379,833 issued July 5, 2022 and U.S. Patent Application 20220300955 filed May 27, 2022.
Speaking Engagements and Presentations
Invited talk to Texas A&M Health Equity Summit on Innovation, Equity, and Human-Centered Data, 2023.
"The Value of Innovation", Keynote address, Mayo Clinic Phoenix Continuing Education Weekend. February 2020.
"Get Engaged! How to Talk to ICER and Anyone Else Forming Opinions About Your Care Coverage", panelist, BIO International Convention. June 2020.
Biobrief
Jennifer Hinkel, MSc CHW FRSA is a business, science, and technology leader with expertise in health outcomes, data, and economics. She is a co-founder and Managing Director of The Data Economics Company and the President of Sigla Sciences, and is a DPhil research student in Evidence Based Health Care at the University of Oxford. She is also a Social Scientist with the Convergent Aeronautics Solutions (CAS) strategic foresight team at NASA working to identify and scope critical problem sets of humankind with a "long-term futures" horizon. She is also the co-Editor-in-Chief of the journal Blockchain in Healthcare Today: Platform Approaches in Health Care.
Previously, she was VP for Strategic Collaborations and later VP of Health Economics and Outcomes Research (HEOR) at cancer diagnostics company Caris Life Sciences. Other prior roles include Senior Partner in a boutique market access consultancy as well as strategic, analytic, and commercial roles at Roche and Genentech in the US, Latin America, and Europe. Ms. Hinkel has also held roles in the non-profit and public sector including at National Comprehensive Cancer Network (NCCN), the Association for State and Territorial Health Officials (ASTHO), and as a researcher for a member of the House of Lords, UK Parliament.
Ms. Hinkel holds degrees from the Georgia Institute of Technology (BS International Affairs) and the London School of Economics (MSc International Health Policy). She has lectured in Health Systems and Health Economics at Penn State University and Arcadia University, holds patents in health care technology and distributed data technology, and has published numerous articles and abstracts related to market access and oncology health services research.
Jennifer is a Fellow of the Royal Society of Arts and a member of the following organizations: Association of Professional Futurists, American Society of Clinical Oncology, European Society of Medical Oncology, American College of Healthcare Executives, Women Business Leaders of the US Health Care Industry, International Society for Pharmacoeconomics and Outcomes Research, British Interplanetary Society, the American Institute of Aeronautics and Astronautics, and the Royal Ocean Racing Club. She is also a certified Community Health Worker for the state of Nevada,
As a survivor of Stage III Hodgkin Lymphoma, Ms. Hinkel has a special interest in oncology innovation. To support the broader survivor and oncology community, Ms. Hinkel founded Resilience Racing, the first all-cancer-survivor sailing team, and also launched the 40 Under 40 in Cancer annual awards program.
Other Projects: Art, Music, Sailing
I compose for musical theater. Here is an example of my latest work-in-progress, Adulting for Beginners, produced as part of a workshop sponsored by the San Francisco Bay Play Café and Musical Café.
I'm an avid sailor and founder of Resilience Racing, the cancer survivor sailing team. We have won some sailing accolades including a class trophy at Cowes Week.
Essays and Blogs
Cancer, Sailing, and Living to the Limit
Stretch, Bounce, Grow: A New Paradigm for Resilience
A Survivor’s Take on Cancer Drugs and the “Moonshot”
Having Cancer Doesn’t Make Me Worth Less
Email:
jennifer dot hinkel at kellogg dot ox.ac.uk